Status:

COMPLETED

Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving

Lead Sponsor:

Medical University of South Carolina

Conditions:

Cocaine Addiction

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The investigators' recently completed study has provided the first evidence that administration of the medication propranolol, following exposure to cocaine cues, can alter drug-associated memories an...

Detailed Description

Three groups of CD (cocaine dependant) participants will receive two sessions of cocaine cue exposure (CCE), each separated by a 24 hr. period and both conducted while the participants remain in hospi...

Eligibility Criteria

Inclusion

  • Participants must meet DSM-IV criteria for current cocaine dependence (within the past month). Participants may meet criteria for abuse, but not dependence, for any other substance with the exception of nicotine. Because of the high comorbidity of cocaine and nicotine dependence, excluding nicotine dependence would seriously compromise the feasibility of recruitment (nicotine patch will be provided to participants during the course of their involvement in the laboratory procedures). Although individuals who meet criteria for alcohol abuse will be accepted for study participation, anyone who has a measurable blood alcohol level on the day of testing will be excluded as acute alcohol intake can lower seizure threshold.
  • Participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.

Exclusion

  • Use of one of the following methods of birth control by female participants: barrier methods (diaphragm or condoms with spermicidal or both), surgical sterilization, use of an intra-uterine contraceptive device, or complete abstinence from sexual intercourse.
  • Individuals must live within a 50-mile radius of our research program and have reliable transportation.
  • Individuals must consent to remain abstinent from all drugs of abuse (except nicotine) for 72 hours immediately prior to CTRC inpatient admission.
  • Individuals must consent to random assignment to one of three study groups (the two propranolol-treated groups or the placebo-treated group).

Key Trial Info

Start Date :

September 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 5 2018

Estimated Enrollment :

181 Patients enrolled

Trial Details

Trial ID

NCT01822587

Start Date

September 1 2013

End Date

November 5 2018

Last Update

December 26 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University of South Carolina

Charleston, South Carolina, United States, 29425